Baseimmune: Revolutionizing Vaccine Development with AI

London-based Baseimmune, a biotech company, has secured €10.4M in funding to develop mutation-proof vaccines using AI. Led by MSD Global Health Innovation Fund and IQ Capital, the funding will accelerate the development of three vaccine candidates for African swine fever, coronavirus, and malaria. Founded in 2019, Baseimmune's innovative technology combines genomic, epidemiological, immunological, and evolutionary data to design universal vaccines effective against current and future variants. With a focus on disrupting the future of pandemic readiness, Baseimmune is at the forefront of revolutionizing vaccine development.